Kryczek Ilona, Wei Shuang, Szeliga Wojciech, Vatan Linhua, Zou Weiping
Department of Surgery, University of Michigan, Ann Arbor, MI, USA.
Blood. 2009 Jul 9;114(2):357-9. doi: 10.1182/blood-2008-09-177360. Epub 2009 Mar 16.
It has been reported that ectopically expressed interleukin-17 (IL-17) in tumor cells suppresses tumor progression through enhanced antitumor immunity in immune competent mice or promote tumor progression through an increase in inflammatory angiogenesis in immune-deficient mice. The role of endogenous IL-17 in tumor immunity remains undefined. Here we showed that tumor growth and lung metastasis were enhanced in IL-17-deficient mice, associated with decreased interferon-gamma(+) natural killer cells and tumor specific interferon-gamma(+) T cells in the tumor draining lymph nodes and tumors. Together with the published data showing that in vitro transforming growth factor-beta and IL-6-polarized Th17 cells induce tumor regression, our work supports the notion that endogenous IL-17 or/and Th17 cells may play a protective role in tumor immunity.
据报道，肿瘤细胞中异位表达的白细胞介素-17（IL-17）在免疫功能正常的小鼠中通过增强抗肿瘤免疫力抑制肿瘤进展，而在免疫缺陷小鼠中则通过增加炎性血管生成促进肿瘤进展。内源性IL-17在肿瘤免疫中的作用仍不明确。在此我们表明，IL-17缺陷小鼠的肿瘤生长和肺转移增强，这与肿瘤引流淋巴结和肿瘤中干扰素-γ（+）自然杀伤细胞及肿瘤特异性干扰素-γ（+）T细胞减少有关。结合已发表的数据表明体外转化生长因子-β和IL-6极化的Th17细胞可诱导肿瘤消退，我们的研究支持内源性IL-17或/和Th17细胞可能在肿瘤免疫中发挥保护作用这一观点。
